<DOC>
	<DOCNO>NCT00008255</DOCNO>
	<brief_summary>RATIONALE : Doctors diagnose lung cancer collect mucus cough lung examine microscope look cancer cell . Breathing INS316 may make easy patient cough mucus . PURPOSE : Randomized phase II trial study effectiveness INS316 help diagnose lung cancer .</brief_summary>
	<brief_title>INS316 Diagnosing Lung Cancer Patients With Untreated Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether cytological diagnosis lung cancer obtain frequently sputum specimen follow inhalation INS316 compare specimen obtain follow placebo compare specimens spontaneously expectorated patient untreated lung cancer . II . Assess relative sensitivity sputum cytology diagnosis lung malignancy patient population use sputum collection regimen . III . Determine quantity macrophage sputum patient use technique . IV . Determine number macrophage sputum obtain method predictive likelihood obtain positive diagnosis lung cancer patient . V. Determine total amount sputum expectorate patient use technique . OUTLINE : This randomize , double-blind , placebo-controlled , cross-over , multicenter study . Patients randomize one two arm , cross-over arm . Arm I : Patients receive INS316 inhalation via nebulizer . Sputum collect throughout dose 1 hour post dosing . Arm II : Patients receive placebo manner INS136 arm I . All patient receive treatment . Patients receive first dose 7 day screen , second dose 3 10 day first dose . Patients follow 1 day completion second treatment . The sputum sample fix examine cytologically . PROJECTED ACCRUAL : Approximately 100-130 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven primary lung cancer OR Presumptive diagnosis base chest xray , CT scan , history , symptoms No prior treatment PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Pulmonary : FEV1 least 35 % predict Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No comorbid condition would preclude study PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 day since prior bronchoscopic examination pulmonary fine needle aspiration biopsy At least 3 day since prior sputum induction No concurrent medication would preclude study At least 30 day since prior investigational drug ( include INS316 ) experimental therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>small cell lung cancer</keyword>
</DOC>